Top 5 Stocks to Buy Now
→ Your book attached (From Profits Run) (Ad)tc pixel Free STX Stock Alerts

Shield Therapeutics (STX) Competitors

Shield Therapeutics logo
GBX 6.50 +0.10 (+1.56%)
As of 06/19/2026 11:49 AM Eastern
Compare

STX vs. ELX, TAO, APC, DGI, and IDEA

Should you buy Shield Therapeutics stock or one of its competitors? MarketBeat compares Shield Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), and Ideagen (IDEA). These companies are all part of the "computer hardware" industry.

How does Shield Therapeutics compare to El Oro?

Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap computer hardware companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Shield Therapeutics presently has a consensus price target of GBX 15, indicating a potential upside of 130.77%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Shield Therapeutics is more favorable than El Oro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
El Oro
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat El Oro's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-35.72% 121.87% -47.85%
El Oro N/A N/A N/A

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.40-£36.28M-£2.00N/A
El Oro-£7.25M0.00N/A-£2.50N/A

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled El Oro'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
El Oro Neutral

Summary

Shield Therapeutics beats El Oro on 9 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to TAO Alpha?

Shield Therapeutics (LON:STX) and TAO Alpha (LON:TAO) are both small-cap computer hardware companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Shield Therapeutics presently has a consensus price target of GBX 15, indicating a potential upside of 130.77%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Shield Therapeutics is more favorable than TAO Alpha.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
TAO Alpha
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

TAO Alpha has lower revenue, but higher earnings than Shield Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.40-£36.28M-£2.00N/A
TAO AlphaN/AN/A-£1.57MN/AN/A

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled TAO Alpha'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
TAO Alpha Neutral

TAO Alpha has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat TAO Alpha's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-35.72% 121.87% -47.85%
TAO Alpha N/A -128.73%-64.09%

6.7% of Shield Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of TAO Alpha shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by insiders. Comparatively, 98.3% of TAO Alpha shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Shield Therapeutics beats TAO Alpha on 8 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to Apc Technology Group?

Shield Therapeutics (LON:STX) and Apc Technology Group (LON:APC) are both small-cap computer hardware companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled Apc Technology Group'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
Apc Technology Group Neutral

Apc Technology Group has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Apc Technology Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.40-£36.28M-£2.00N/A
Apc Technology Group£19.20M0.00N/A£0.50N/A

Apc Technology Group has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat Apc Technology Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-35.72% 121.87% -47.85%
Apc Technology Group N/A N/A N/A

Shield Therapeutics presently has a consensus price target of GBX 15, indicating a potential upside of 130.77%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Shield Therapeutics is more favorable than Apc Technology Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Apc Technology Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Shield Therapeutics beats Apc Technology Group on 7 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to DG Innovate?

DG Innovate (LON:DGI) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Shield Therapeutics has a consensus price target of GBX 15, suggesting a potential upside of 130.77%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than DG Innovate.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DG Innovate
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

8.0% of DG Innovate shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 45.7% of DG Innovate shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DG Innovate has a beta of 3.55, suggesting that its stock price is 255% more volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.779, suggesting that its stock price is 78% more volatile than the broader market.

In the previous week, DG Innovate's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
DG Innovate Neutral
Shield Therapeutics Neutral

DG Innovate has higher earnings, but lower revenue than Shield Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DG Innovate£24.50K0.00-£4.91MN/AN/A
Shield Therapeutics£49.70M1.40-£36.28M-£2.00N/A

DG Innovate has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat DG Innovate's return on equity.

Company Net Margins Return on Equity Return on Assets
DG InnovateN/A -129.16% -50.26%
Shield Therapeutics -35.72%121.87%-47.85%

Summary

DG Innovate and Shield Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Shield Therapeutics compare to Ideagen?

Shield Therapeutics (LON:STX) and Ideagen (LON:IDEA) are both small-cap computer hardware companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Ideagen has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Ideagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.40-£36.28M-£2.00N/A
Ideagen£75.28M0.00N/A£0.02N/A

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled Ideagen'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
Ideagen Neutral

Shield Therapeutics currently has a consensus target price of GBX 15, suggesting a potential upside of 130.77%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Ideagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ideagen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ideagen has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat Ideagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-35.72% 121.87% -47.85%
Ideagen N/A N/A N/A

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Shield Therapeutics beats Ideagen on 6 of the 11 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STX vs. The Competition

Export
MetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£69.52M£2.42B£6.43B£2.88B
Dividend YieldN/A2.95%2.68%6.15%
P/E Ratio-3.254.9320.94366.85
Price / Sales1.401,647.58529.7286,443.43
Price / Cash6.3610.1845.0727.85
Price / Book118.7810.9510.808.01
Net Income-£36.28M£20.27B£3.57B£5.89B
7 Day Performance1.56%-1.12%0.73%0.08%
1 Month Performance-0.23%4.87%1.35%1.15%
1 Year Performance154.90%13.64%29.31%72.12%

Shield Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STX
Shield Therapeutics
1.205 of 5 stars		GBX 6.50
+1.6%		GBX 15
+130.8%		+172.2%£69.52M£49.70MN/A40,000
ELX
El Oro
N/AN/AN/AN/A£41.06M-£7.25MN/A1,122
TAO
TAO Alpha
N/AGBX 7.10
+31.5%		N/A+36.5%£26.89MN/AN/A3
APC
Apc Technology Group
N/AN/AN/AN/A£18.03M£19.20M19.75164,000
DGI
DG Innovate
N/AN/AN/AN/A£1.90M£24.50KN/A790

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:STX) was last updated on 6/20/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
An Elon Musk Fan's Warning About SPCX
Jon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...
Banyan Hill Publishing | Sponsoredtc pixel